Elaine Jones Increases Stake in NXTC

Elaine Jones, an insider, bought 2,340 shares of NXTC on June 18, 2026. The transaction was not part of a pre-planned trading program. Shares of NXTC traded at $1.75 on the same day.

Insider Buying and Selling at NextCure, Inc.

Several insiders, including Elaine Jones, Feigal Ellen, Borgman Anne Elizabeth, Houston John, and Webster Stephen, each bought 2,340 shares of NXTC. David Kabakoff purchased a larger amount of 3,510 shares, all on June 18, 2026. These transactions were not planned under Rule 10b5-1.

Other Institutional Activity in NXTC

Squadron Capital Management LLC increased its holdings in NXTC by 28,034 shares, bringing its total to 265,000 shares valued at approximately $2.83 million, an 11.8% increase. Affinity Asset Advisors, LLC reduced its stake by 5,468 shares, now holding 241,826 shares worth about $2.58 million, a 2.2% decrease. Ikarian Capital, LLC maintained its position with 238,303 shares valued at $2.51 million. Sofinnova Investments, Inc. also held steady with 222,654 shares worth $2.38 million. Vanguard Capital Management LLC opened a new position with 160,473 shares valued at $1.69 million.

Analysts Set New Price Targets

On May 11, 2026, Lucid Capital Markets initiated coverage on NXTC with a "buy" rating and a price target of $25. Ladenburg Thalmann upgraded the stock to a "buy" with an $18 target on November 7, 2025. Piper Sandler maintained its "buy" rating with a $15 target on July 15, 2025. HC Wainwright & Co. reiterated its "buy" rating with a $3 target on July 1, 2025.

Bottom Line

Insider buying activity at NXTC, including purchases by Elaine Jones and others, signals confidence from those closely associated with the company. Institutional investors are also actively adjusting their positions, with some increasing and others reducing their holdings. Analysts have shown optimism with recent "buy" ratings and significant price targets. This activity is of interest to investors tracking NXTC's market moves.